Aidez-nous à améliorer ce site en répondant à un court sondage. Cliquez Ici

Cameron Brink achieves visual freedom with the EVO implantable lenses

Basketball Player

Cam Brink 80 41

Vision struggles on and off the court

Cameron Brink, a star on the women’s basketball team of Stanford University, faced the daily struggles of glasses and contacts, impacting both her personal and professional life.

Cameron Brink High Res v2

EVO ICL: the game-changer

Cameron's vision problems started in the 5th grade when glasses became a part of her daily life. Later, her reliance on visual aids expanded to contacts, introducing a new set of challenges. For approximately 12 years, Cameron navigated the world through glasses and contacts. "I've been wearing glasses or contacts since I was in the 5th grade. And started to struggle with eye dryness and irritation. As a basketball player, I was constantly losing my contacts during games and practice!" The burden of being nearsighted became an accepted norm… until Cameron learned about the EVO Implantable Collamer® Lenses (EVO ICL).
Cameron's decision to correct her nearsightedness with the EVO ICL procedure was fueled by the desire to break free from the constraints of traditional vision correction methods. With EVO ICL, Cameron's life took a remarkable positive turn. "My life has changed for the better! I don't have to fumble with contacts anymore when I wake up or during the day, and my eyes aren't irritated anymore. Plus, I don't have to worry about losing lenses on the court!"
The differences post-EVO ICL are noticeable. In Cameron's words, "my eyes aren't irritated and dry like they were when I wore contacts. And I love waking up in the morning seeing clearly." Cameron emphasizes the life-changing benefits that extend beyond the basketball court. Choosing EVO ICL was not just about vision correction; it was a lifestyle choice. "The time I save each day! Living a life free of contacts was a huge selling point; as well as the fact that the EVO lens implant is reversible if I ever need it."
Cam Brink1
Cam Brink5
Cam Brink6

Join her in experiencing the world with newfound clarity and confidence. For those on the fence about EVO ICL, Cameron passionately encourages,

"Talk to your eye doctor today. It's truly a life-changing procedure!"

Ready to embrace a life without the hassle of glasses and contacts? Discover the possibilities with EVO ICL. Call an EVO advisor today to schedule an appointment with an eye doctor near you, and embark on your own journey towards visual freedom!

Informations de sécurité importantes concernant l'EVO/EVO+ ICL

L'EVO/EVO+ ICL est destiné aux patients âgés de 21 à 60 ans et est offert avec des puissances sphériques allant de -3,0 D à -18,0 D pour la correction ou la réduction de la myopie, avec ou sans puissance cylindrique, dans une plage de 1,0 D à 6,0 D. L'implantation de l'EVO/EVO+ ICL est une intervention chirurgicale et comporte, à ce titre, des risques potentiellement graves. Voici quelques complications/événements indésirables possibles : interventions chirurgicales additionnelles, formation de cataracte, perte temporaire ou permanente de la meilleure acuité visuelle corrigée, augmentation de la pression intraoculaire, perte de cellules à la surface la plus interne de la cornée, irritation conjonctivale, œdème cornéen, irritation conjonctivale, endophtalmie (infection totale de l'œil), éblouissements importants et/ou halos autour des lumières, hyphéma (sang dans l'œil), hypopyon (pus dans l'œil), infection oculaire, luxation de l'EVO/EVO+ ICL, œdème maculaire, pupille non réactive, glaucome par bloc pupillaire, inflammation oculaire sévère, irite, uvéite, perte du vitré et greffe de cornée. Avant d’envisager une chirurgie EVO/EVO+ ICL, vous devriez subir un examen complet des yeux et discuter avec votre professionnel des soins oculaires de la procédure EVO/EVO+ ICL, en particulier des avantages potentiels, des risques et des complications. Vous devriez aussi discuter du temps de guérison nécessaire après la chirurgie.

Références

Select Your Region

Europe

AustriaBelgium - DutchBelgium - FrenchFranceGermanyItalyNetherlandsNorwayPolandPortugalSpainSwedenSwitzerland - FrenchSwitzerland - GermanSwitzerland - ItalianUK & Ireland

North America

CanadaCanada - FrenchMexicoUnited StatesUnited States - 中文

Latin America

BrazilEnglishSpanish

North Africa

Arabic

Middle East

Middle East عربىMiddle East - فارسي

Asia Pacific

AustraliaChina - 中国IndiaJapan - 日本New ZealandS. Korea - 대한민국South East Asia

Références

1. Patient Survey, STAAR Surgical ICL Data Registry, 2018

2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018

3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council